The Safety and Efficacy of Combined Amitriptyline and Tranylcypromine Antidepressant Treatment

Razani, Javad; White, K. Geoffrey; White, Judith L.; Simpson, George M.; Sloane, R. Bruce; Rebal, Ronald; Palmer, Ruby

doi:10.1001/archpsyc.1983.04390010067008

Cited by 96 publications

(27 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nevertheless, a number of case reports and open label series from the 1960s (Sargant, 1963;Gander, 1965;Dally, 1965), 1970s (Ray, 1973;Winston, 1971;Schuckit et al, 1971;Sethna, 1974;Spiker and Pugh, 1976), and 1980s (Schmauss et al, 1986(Schmauss et al, , 1988 suggest that these agents may be synergistically effective, when used in combination (Table 5). The safety of this TCA-MA01 combination has been demonstrated in two controlled trials in nonresistant depressed patients (Razani et al, 1983;Young et al, 1979). This combination appears to be well tolerated when moderate to low doses of both agents are used, and when the MA01 is added to an established TCA dose (Goldberg and Thornton, 1978;White and Simpson, 1981).…”

Section: Combining Tcas and Maoismentioning

confidence: 95%

“…The safety of this TCA-MA01 combination has been demonstrated in two controlled trials in nonresistant depressed patients (Razani et al, 1983;Young et al, 1979). However, results of these studies do not indicate that the MAOI-TCA combination is more effective than either agent used alone in adequate dosages (Razani et al, 1983;Young et al, 1979). However, results of these studies do not indicate that the MAOI-TCA combination is more effective than either agent used alone in adequate dosages (Razani et al, 1983;Young et al, 1979).…”

Section: Combining Tcas and Maoismentioning

confidence: 98%

See 1 more Smart Citation

Tricyclics and newer antidepressant medications: Treatment options for treatment‐resistant depressions

et al. 1994

View full text Add to dashboard Cite

Only about 60-70% of those depressed patients who can tolerate an antidepressant medication, and only about SO-60% of those who begin a medication will respond to the Frst trial. Furthemnore, S-10% will remain depressed despite multiple medication trials. When the disorder is poorly responsive, it is variously described as a resistant, refractory, or intractable depression. This review summarizes the available literature on treatment-resistant depression (TRD) to provide recommendations for the most rational alternative strategies. Depression 2: 1S2-168 (1994/1995). @ 199s Wiley-Liss, Inc.

show abstract

Section: Combining Tcas and Maoismentioning

confidence: 95%

Section: Combining Tcas and Maoismentioning

confidence: 98%

Tricyclics and newer antidepressant medications: Treatment options for treatment‐resistant depressions

et al. 1994

View full text Add to dashboard Cite

show abstract

“…Controlled trials do not support the use of MAOI-TCA combinations in refractory depression (Davidson et al, 1978;Young et al, 1979;White et al, 1980;Razani et al, 1983). Nevertheless numerous reports suggest it is effective and relatively safe in experienced hands (White & Simpson, 1984).…”

Section: Combined Antidepressantsmentioning

confidence: 99%

Dealing with persisting abnormalities of mood

Scott

Cole

Eccleston

1991

International Review of Psychiatry

View full text Add to dashboard Cite

A signifcant minority (between 12-20%) ofpatients with affective disorder sufferfrom persisting abnormalities of mood. Individuals with these disorders represent a heterogeneous group spanning the neuroses and the psychoses. This review outlines our current knowledge of the aetioloa and classification of persistent mood disorders. The most prevalent persistent abnormality in bipolar patients is rapid cycling disorder, whilst those with unipolar illnesses are more likely to sufferborn chronic depression, The management of these two problems is discussed in detail. Although these patients fall into the 'difficult to treat' category, recent research suggests that multimodal treatment including optimal pharmacotherapy and appropriate psychosocial interventions can lead to signifcant improvement in at least 50% of cases.

show abstract

“…There has been recent evidence (White & Simpson 198 1 ; Lader 1 983; Razani et al 1983) to suggest that the combination is safe when used under strictly specified conditions (i.e., the drugs should be used simultaneously at low dose, and tranylcypromine and clomipramine should be specifically avoided).…”

Section: Combination Of Tricyclic Antidepressants and Monoamine Oxidamentioning

confidence: 99%

The Pharmacological Treatment of Tricyclic-Resistant Depression: Review and Management Guidelines

Mitchell

1987

Aust N Z J Psychiatry

View full text Add to dashboard Cite

Despite the introduction of a wide range of antidepressant drugs since the late 1950s, approximately 30-50% of depressed subjects do not respond to these agents. Various treatment strategies, both pharmacological and non-pharmacological, have been proposed for treatment-resistant depression. This paper critically reviews the studies of single and combined pharmacological treatments for tricyclic-resistant patients, with a particular discussion of lithium augmentation. The major inadequacies of these studies have been the frequent lack of definitions of treatment resistance, the heterogeneity of the depressed samples, and the infrequent use of double-blind, placebo-controlled designs. Two central issues, definition of treatment resistance and clinical predictors of response to pharmacological treatments, are discussed in detail. Finally, a suggested guideline for the management of tricyclic-resistant depression is proposed.

show abstract

The Safety and Efficacy of Combined Amitriptyline and Tranylcypromine Antidepressant Treatment

Cited by 96 publications

References 22 publications

Tricyclics and newer antidepressant medications: Treatment options for treatment‐resistant depressions

Tricyclics and newer antidepressant medications: Treatment options for treatment‐resistant depressions

Dealing with persisting abnormalities of mood

The Pharmacological Treatment of Tricyclic-Resistant Depression: Review and Management Guidelines

Contact Info

Product

Resources

About